Ritter Pharmaceuticals, Inc. (RTTR) EPS Estimated At $-0.05

February 14, 2018 - By reb123z

 Ritter Pharmaceuticals, Inc. (RTTR) EPS Estimated At $ 0.05

Analysts expect Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) to report $-0.05 EPS on February, 26.They anticipate $0.69 EPS change or 93.24 % from last quarter’s $-0.74 EPS. After having $-0.14 EPS previously, Ritter Pharmaceuticals, Inc.’s analysts see -64.29 % EPS growth. The stock increased 1.28% or $0.0038 during the last trading session, reaching $0.3018. About 199,997 shares traded. Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) has declined 56.21% since February 14, 2017 and is downtrending. It has underperformed by 72.91% the S&P500.

Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) Ratings Coverage

Among 5 analysts covering Ritter Pharmaceuticals (NASDAQ:RTTR), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Ritter Pharmaceuticals had 9 analyst reports since December 2, 2015 according to SRatingsIntel. As per Monday, October 23, the company rating was maintained by H.C. Wainwright. The rating was maintained by Roth Capital on Monday, June 5 with “Buy”. The firm has “Buy” rating given on Wednesday, January 4 by Rodman & Renshaw. The rating was maintained by Maxim Group with “Hold” on Wednesday, July 5. On Thursday, April 14 the stock rating was initiated by Maxim Group with “Buy”. The rating was maintained by Chardan Capital Markets with “Buy” on Tuesday, October 25. On Wednesday, December 2 the stock rating was initiated by Chardan Capital Markets with “Buy”. The firm has “Hold” rating given on Friday, August 4 by Maxim Group.

Ritter Pharmaceuticals, Inc., a specialty pharmaceutical company, develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The company has market cap of $14.94 million. The Company’s lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b/3 clinical trial for the reduction of symptoms associated with lactose intolerance. It currently has negative earnings. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine.

More notable recent Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) news were published by: Globenewswire.com which released: “Ritter Pharmaceuticals Reports Third Quarter 2017 Financial Results and …” on October 31, 2017, also Globenewswire.com with their article: “Ritter Pharmaceuticals, Inc. Raises $23 Million to Fund Initiation of Its …” published on October 03, 2017, Labusinessjournal.com published: “Ritter Pharma Raises $23 million to Test Lactose Intolerance Treatment” on October 04, 2017. More interesting news about Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) were released by: Globenewswire.com and their article: “Ritter Pharmaceuticals Presents at the 10th Annual LD Micro Conference on …” published on November 29, 2017 as well as Globenewswire.com‘s news article titled: “Ritter Pharmaceuticals Presents at the 5th Microbiome R&D Business …” with publication date: November 02, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.